# Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder

> **NCT02919501** · PHASE2 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 55 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** Vortioxetine (IV)
- **OTHER:** Placebo (IV)
- **DRUG:** Vortioxetine (tablet)

## Key facts

- **NCT ID:** NCT02919501
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-27
- **Primary completion:** 2017-04-27
- **Final completion:** 2017-04-27
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2018-06-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02919501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02919501, "Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02919501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*